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Abstract. – OBJECTIVE: Lymphoedema of 
the extremities is a widespread pathological 
condition that mostly occurs as a complication 
of cancer resections, especially in women. Con-
ventional therapy refers to conservative and 
physiotherapeutic approaches. Surgical strate-
gies have been widely reported in the literature 
and are still challenging. Part of this literature 
focuses on the supra microsurgical lymphati-
covenular anastomosis (LVA) technique. LVA is 
characterized by a high success rate, minimal 
invasivity and broad indications. Furthermore, 
this procedure can be performed under local an-
esthesia. 
PATIENTS AND METHODS: From October 
2011 through October 2014, 69 patients affected 
by lymphedema underwent LVA surgery in Sie-
na University Hospital, Italy. Preoperative and 
postoperative evaluations were taken. 
RESULTS: Totally, 366 anastomosis have 
been performed. The average rate was 5.3 anas-
tomosis per patient. All patients registered a 
decrease in the size of the affected side. The av-
erage volume reduction was 50%. Patients also 
showed a reduction of lymphangitis episodes 
and reduction of compression garments class. 
Moreover, a satisfaction index was evaluated. 
The majority of patients (72.5%) was extremely 
satisfied of the surgery.   
CONCLUSIONS: LVA has demonstrated to 
be an effective surgical strategy to treat lymph-
oedema, especially in secondary cases in early 
stages. Although LVA is widely discussed in 
the literature, the majority of works relates to 
Japanese authors and few reports exist outside 
Japan. This paper represents the very first ret-
rospective analysis of the adoption of LVA tech-
nique in Italy and one of the few outside Japan.
Key Words
Lymphoedema, Surgical treatment, Supramicrosur-
gery, Lymphaticovenular anastomosis, Indocyanine 
green, Lymphography, ICG, LVA.
Introduction
Lymphoedema of the extremities is a chronic 
pathological condition determined by an output 
failure in lymphatic flow with subsequent pro-
gressive persistent edema. It mainly occurs as a 
complication of radical resections of various can-
cers, especially, but not only, in women. Current 
treatment of lymphoedema is based on conserva-
tive therapies and consists of manual lymphatic 
drainage, intermittent pneumatic therapy, mul-
tilayered bandages and compression garments. 
Also, surgical approaches have been described. 
Surgical strategies include liposuction, excisional 
procedures and microvascular surgery.
Thanks to the advancements in microsurgery 
and the introduction of supra microsurgery, a 
novel technique has been developed. This proce-
dure, known as lymphaticovenular anastomosis 
(LVA), offers a high rate of positive outcomes 
with a minimally invasive surgical approach. In 
this paper, the authors offer a retrospective analy-
sis of 69 patients affected by monolateral upper or 
lower extremities lymphoedema, treated adopting 
LVA. A 36 months follow-up is presented. Al-
though LVA has been well documented in the lit-
erature, the majority of works relates to Japanese 
experience and few reports exist outside Japan, 
especially in Europe. In this paper, the authors 
present the first Italian report.
Patients and Methods 
Retrospective analysis of 36 months follow-up in 
69 patients is presented. From October 2011 through 
October 2014, 69 patients affected by monolateral 
upper or lower extremities lymphoedema under-
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went LVA surgery in our department. All patients 
were operated at Siena University Hospital by one 
of the authors. The nature and possible risks of the 
study had been described in details to each patient 
and written informed consent was obtained. Of the 
69 patients, 64 were females (93%) and 5 were male. 
Mean patient age was 55 years old (range: 16 to 76). 
60 patients (87%) suffered from secondary lymph-
oedema after cancer resection, 1 was a secondary 
case after a traumatic injury, while 9 were primary 
cases. 42 patients (61%) have been treated for up-
per extremities lymphoedema whereas 27 patients 
presented the pathology in the lower extremities. 
The majority, 40 patients (58%), reported a history 
of breast cancer; 9 patients (13%) showed endome-
trial cancer; 3 (4%) patients were affected by mel-
anoma and underwent lymphadenectomy; 2 (3%) 
patients were treated for ovarian cancer; 2 (3%) 
patient was treated for cervical cancer; 1 (1.5%) 
patient presented a history of sarcoma; 1 (1.5%) pa-
tients was treated for bladder cancer and underwent 
lymphadenectomy; 1 (1.5%) patient was treated for 
prostate cancer; 9 patients (13%) were primary case 
and 1 (1.5%) patient presented lymphoedema arisen 
after a traumatic injury.
39 patients (57%) underwent radiotherapy. 
The average lymphoedema duration was 5.8 
years (range 1-23). 
Each patient was evaluated according to the 
guidelines established by the International So-
ciety of Lymphology. In particular, 39 patients 
(57%) presented stage III, 27 patients (39%) pre-
sented stage IV and 3 patients (4%) stage. 
Also, we analyzed cellulitis episodes: 34 pa-
tients (49%) suffered from cellulitis episodes in 
the previous years.
Each patient was evaluated before and af-
ter surgery: preoperatively ultrasonography, 
echo-color-Doppler of the venous system and 
bilateral multiple circumferential measurements 
of the extremities were taken. The measurements 
of the upper extremities were taken at the palm 
of the hand, at wrist, 5 cm below the elbow, at 
the elbow and 5 cm above the elbow. As for the 
lower extremities measurement were taken at foot 
dorsum, at the ankle, 10 cm below the inferior 
margin of the patella, at the patella and 10 cm 
above. Additionally, the same measures of the 
specular healthy limb were recorded.
The difference in size between the affected 
and the contralateral healthy side was also taken. 
1 year after surgery and at each subsequent visit 
multiple circumferential measurements were tak-
en every time.
Then, the preoperative and postoperative sum 
of measures were confronted. 
Body weight was evaluated before surgery 
and at every visit after surgery in order to con-
sider variation in volume due to adipose tissue: 
none of the patients had an increase or reduction 
in weight (> 3 kg) which would have resulted in 
the exclusion from the study.
Preoperatively, the patients underwent to in-
docyanine green dye (ICG) lymphography. For 
upper extremities, 0.1 ml indocyanine green was 
injected subcutaneously at the second web space 
of the hand and the ulnar border of the palmaris 
longus tendon at the level of the wrist. For lower 
extremities, 0.2 ml of indocyanine green dye 
were injected at the first web space of the foot and 
the tibial aspect of the ankle.
After injection lymphatic drainage was studied 
using an infrared camera system (Photodynamic 
Eye (PDE); Hamamatsu Photonics, Hamamatsu 
City, Shiznoka, Japan). Results were evaluated 
according to the classification described by Yama-
moto1. In particular, 30 patients (44%) presented 
stardust pattern, 25 patients (36%) diffuse pattern, 
14 patients (20%) splash pattern2.
Postoperatively patients have been asked to 
evaluate their feelings after LVA. The satisfac-
tion index consisted of questions regarding the 
patient’s clinical conditions and quality of life be-
fore and after LVA and was established as a 1 to 
4 scale (1= not satisfied; 4= extremely satisfied).
Anesthesiologic consideration
Local anesthesias were performed adopting 
a mixture of 2% lidocaine and epinephrine at a 
dilution of 1:200,000. Since the intervention re-
quires immobility, deep sedation was adopted to 
increase patient’s comfort. Propofol (2 mg/kg/h) 
and Remifentanil (0.015 mcg/kg/min) were used 
while maintaining spontaneous breathing. Oxy-
gen was administrated at 4l/min via nasal cannu-
la or Venturi’s mask. Patients were premedicated 
with Midazolam (0.02 mg/kg). Antibiotic pro-
phylaxis, gastric protection as well as antiemetic 
were used. Patients were monitored during the 
surgical procedure. Adequate postoperative anal-
gesia was obtained with acetaminophen 1 g every 
8 hours for the first 24 hours.
Operative technique
LVA was performed under local anesthesia. Ac-
cording to the patient’s conditions and compliance. 
Patients undergoing LVA under local anesthesia 
were allowed to move the limb and have some rest 
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between the incisions. Multiple (range 3-5) 2 cm 
linear skin incisions were performed. Sites of inci-
sions were chosen according to ICG lymphography 
findings. Microscopic dissection was carried out 
in order to identify lymphatic vessels and venules. 
Lymphatic vessels were prepared and sutured to 
veins using 11-0 or 12-0 sutures. (Figure 1).
For the lower extremities, incisions were per-
formed on thin adipose portions such as the me-
dial aspect of the pretibial areas of the proximal 
and middle lower leg and ankle. Lymphatics 
were detached between adipose particles in the 
superficial or deep adipose layer and sometimes 
in the subdermal layer. As for the upper extremi-
ties, the lateral and medial aspects of the forearm 
and snuff box were suitable for incisions. The 
subdermal venules, which exist anywhere under-
neath the dermis, were found in the proximity of 
lymphatics. These venules presented low blood 
pressure which is demonstrated by the absence of 
backflow. After anastomoses have been complet-
ed, lymphatic flow was observed into the venules.
Patients were dismissed the day after surgery 
and received oral antibiotic therapy for 6 days.
Patients were evaluated at 2 weeks, 1 month, 
and every 6 months after surgery. Two weeks 
after surgery stitches were removed.
Results
The authors evaluated results in patients with 
at least one-year follow-up (Table I).
Totally, 366 anastomoses have been performed 
with an average rate of 5.3 anastomoses for patient.
The average duration of the procedure was 
180 minutes. Surgeries were performed by two 
operators using one or two microscopes. No com-
plications were observed postoperatively. After 
surgery, patients received the same physiotherapy 
they adopted before. In particular, they were en-
couraged to undergo lymphatic drainage and to 
wear a compression stocking for 12 months. 
Every patient registered a decrease in the size 
of the affected side.
No patient incurred in worsening of the dis-
ease after surgery. The average size reduction 
was 50% (range 11-98%). The average reduction 
in the secondary lymphoedema was 49% (range 
11-98%), while the average in the primary was 
61% (range 41-87%) (Table II) (Figures 2, 3, 4).
The average reduction in patients presenting 
“splash” pattern at ICG lymphography was 63%, 
in “stardust” pattern 56% and 36% in “diffuse” 
pattern.
The average reduction in patients who never had 
lymphangitis was 55%, while was 49% in patients 
who had 1 or 2 episodes of cellulitis, and 33% in 
patients with a history of more than 2 episodes.
The average reduction in patients who have 
had lymphoedema for less than 2 years was 58%, 
and was 49% in the others.
Every patient (100%) who suffered from cel-
lulitis before surgery reported no episodes after 
surgery during the follow-up period. 
Also, post-operative ICG lymphography was 
taken. Patency of anastomosis was observed in 
337 anastomoses of 366 (92%) (Figure 4).
67 patients (97%) were satisfied of their clin-
ical improvement after LVA. 2 patients were not 
fully satisfied. The average satisfaction level was 
3.7 point on a 4-point scale. Also, they reported a 
reduction in heaviness, hardness, functional im-
pairment and pain of the affected limb.
Figure 1. Intraoperative view. Lymphatic and vein can be seen before (left side) and after (right side) double anastomosis. Mean 
diameter of these vessels were 0.5 mm; 11.0 suture was adopted.
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Table II. The figure shows the comparison between the differences in measurements between the affected and healthy limb: 
the blue lines show the difference in measurements between the sick and the healthy limb before surgery, the red lines show the 
difference during follow-up. We can see that the surgery has reduced the size of the limb in all patients.
Figure 2. A patient preoperative and postoperative view. An important reduction in size of the affected extremities can be seen. 
This patient experienced an early treatment which is the best indication for LVA surgery with successful result.
P. Gennaro, G. Gabriele, M. Mihara, K. Kikuchi, C. Salini, et al.
4650
Patients also reported an increased efficacy 
of physiotherapy after LVA. In particular, 56 pa-
tients (81%) reported a reduction of compression 
class of garments. 
We also applied a significance test to the 
results we have obtained. Assuming a normal 
distribution of our population, we performed a 
test to check for equality between the average of 
our two samples using two-sided t-tests. The test 
rejects the null hypothesis of equality between 
the means and, with a p-value of 0.027, provides 
statistical evidence that there is a significant dif-
ference between the size of the limbs before and 
after the surgery. Therefore, it can be concluded 
that the LVA surgery has led to a significant re-
duction in limb size.
Figure 3. A patient preoperative and postoperative view. Reduction of edema is visible especially on the hand.
Figure 4. A patient preoperative and postoperative evaluation: a slight reduction of edema can be appreciated. Red lines show 
lymphatic vessels after ICG-lymphography. Also the sites of injection can be seen.
Supramicrosurgical LVA in treating lymphoedema
4651
Discussion
Lymphoedema of the extremities is a chronic 
pathological condition determined by an output 
failure in lymphatic flow with subsequent pro-
gressive edema. Lymphoedema could appear as a 
primary or secondary disease. Secondary lymph-
oedema mostly occurs as a consequence of the 
surgical treatment of various cancers, especially 
in women. Lymphoedema due to filariasis is seen 
as endemic in tropical regions of Africa, South 
Asia, and South America. Other types of second-
ary lymphedema include obstruction of lymphat-
ics due to traumas or secondary compression3.
Notably, current treatment of lymphedema 
is based on conservative therapies consisting in 
manual lymphatic drainage, intermittent pneu-
matic therapy, multilayered bandages and com-
pression garments. Földi introduced the method-
ology of combined physiotherapy, intermittent 
pneumatic compression, and skin care. However, 
such approaches, not addressing the physiopa-
thology of the disease, are time-consuming and 
lack satisfactory results4.
Surgical management of lymphoedema has 
been described. Surgical approaches include lipo-
suction, excisional procedures, and microvascular 
surgery. Also, Kinmonth et al5 described island 
ileum transfer to the inguinal lymph region, 
aimed to the drainage via mesenteric lymph sys-
tems. However, although these strategies were 
worldwide accepted and success was reported in 
some patients, their effectiveness has never been 
consistent. Lymphaticovenular anastomosis was 
firstly reported in 1969 by Yamada6; according to 
this method, the proximal end of the transected 
lymph vessel is sutured to the main trunk of a 
large cutaneous vein in end-to-side fashion.
Subsequently, Koshima et al7 standardized the 
technique introducing minimally invasive supra 
microsurgical approach for lymphaticovenular 
anastomosis.
LVA is designed as a bypass procedure aiming 
to restore lymph drainage and to treat edema on a 
long-term basis8,9. Recent super- (or supra) micro-
surgical techniques made possible the precise anas-
tomosis of vessels of 0.8 to less than 0.2 mm caliber 
using 11-0 or 12-0 nylon with 50 to 70 µm needle10.
Supra microsurgical LVA differs from tradi-
tional lymph-venous bypass surgery because it 
requires microvascular anastomosis while accord-
ing to the traditional technique a lymphatic tissue 
is inserted in a larger vein. The venules adopted 
for supra microsurgical LVA are subdermal veins 
whit a caliber of few millimeters: these venules, 
because of their low pressure, do not show back-
flow; therefore, after the anastomosis is complet-
ed, the wash-out of lymph into the venule can be 
appreciated. 
Furthermore, although satisfactory results 
have been described adopting traditional LVA 
technique, surgically approaching the axillary or 
groin area can result in a difficult identification 
of lymphatics because of retracted or irradiated 
tissue. In this district surgical complications may 
produce a worsening of lymphoedema.
Moreover, as described by Yamamoto et al11, 
in lymphoedema patients the degeneration of 
lymphatic system runs from proximal to distal 
side: lymphatics adopted for supra microsurgi-
cal LVA are peripheral vessels which present a 
major functional reserve. In addition, this kind 
of vessels can be easily detached around distal 
joints and at ICG lymphography show linear pat-
tern. Furthermore, supra microsurgical LVA is 
characterized by a minimal invasivity and can be 
performed under local anesthesia.
Preoperative indocyanine green (ICG) lym-
phography has demonstrated its clinical effec-
tiveness in clinical staging and in detaching 
appropriate lymphatics vessels12.
However, although it is easier for surgeons to 
found good lymphatic vessels in patients showing 
“linear” pattern, the authors agree that lymphat-
ics can be find even if ICG-lymphography show 
“splash” or “stardust” dermal backflow pattern. 
However, lymphatics can rarely be spotted in 
“diffuse” dermal backflow pattern. Moreover, 
performing ICG- lymphography in the contralat-
eral healthy extremity helps to select the site of 
the incision on the affected side13.
Also, ICG-lymphography is a noninvasive, non-
radioactive test that allows real-time evaluation of 
superficial lymphatic system14. Moreover, in lymph-
oedema patients, a fibrotic involution of lymphatic 
vessels could be seen15. The LVA technique also 
aims to stop the progression of fibrogenesis affect-
ing lymphatic vessels which stand remarkable point 
in a progressive pathology. The timing of the occlu-
sion and degeneration of the smooth muscle cells 
may not directly correspond to the edema duration. 
This means that can be worth trying a lymphaticov-
enular anastomosis even in patients with a duration 
of lymphoedema of more than 20 years16.
Furthermore, the use of LVA, on bypasses 
performed at different sites on the affected ex-
tremity, is likely to give benefits also in seriously 
compromised areas17.
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LVA has shown a high success rate and broad 
indications. Best results can be achieved in pa-
tients presenting mild lymphoedema in early 
stages, and outcomes can be analyzed objectively 
and subjectively. As for objective outcomes, LVA 
has demonstrated a decrease in the circumference 
of the affected extremities and a severe contrac-
tion of cellulitis episodes18. 
Postoperative ICG lymphography was taken 
to demonstrate the patency of anastomosis. 92% 
of anastomosis was working 1 years after surgery. 
As far as subjective outcomes are concerned, 
patients feel their extremities lighter and softer. 
Physiotherapy is considered much more effective 
after LVA. Additionally, strength class of garment 
has been reduced19. Therefore, every patient can 
benefit from this technique. Moreover, remission 
of lymphoedema can be achieved at an early 
stage. Indeed, future perspectives should be fo-
cused on preventive intervention in patients at 
risk for the development of a lymphoedema. 
Conclusions
Surgical treatment of lymphoedema is still chal-
lenging and an unanimous consensus on princi-
ples, indications and outcomes are still far to be 
achieved. Lymphaticovenular anastomosis (LVA) is 
characterized by broad indications and high success 
rate. LVA has also the unquestionable advantage of 
the extremely minimal invasivity which allows to 
perform the procedure under local anesthesia and 
in patients whose conditions would advise against 
general anesthesia. LVA has demonstrated to be an 
effective surgical strategy to treat lymphoedema, 
especially in patients affected by secondary lymph-
oedema in early stages. Although LVA has been 
well documented in the literature, the majority of 
works relates to Japanese experience and few re-
ports exists outside Japan, especially in Europe. The 
present paper represents the first Italian report about 
supra microsurgical LVA.
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